Zeaxanthin

Evidence Fact Sheet

Educational reference page covering the macular xanthophyll family — the three stereoisomers (lutein vs 3R,3′R-zeaxanthin vs meso-zeaxanthin), the radial macular pigment gradient that anchors the entire field, what the AREDS2 / CREST / MOST AMD / ZVF / MacuPrime trial record actually supports, and the two regulatory and three editorial caveats that quietly mis-represent half of all consumer zeaxanthin marketing. This sub-page sits inside the carotenoids cluster hub alongside the macular-pair partner lutein sub-page. Not medical advice.

Last reviewed 2026-05-24 · How we assess evidence →

§1 · Quick Summary (60-second read)

Zeaxanthin is one of only two carotenoids that deposit in the human macular pigment (the other is its stereoisomer-partner lutein). Together they form a built-in optical filter at the retina's highest-acuity region, with absorption peaking in the high-energy blue band at ~470 nm and a parallel singlet-oxygen-quenching antioxidant function. The story is mechanistically rich and clinically well-studied — but it is also one of the most consistently mis-cited stories in consumer nutrition.

Three things to know before you read any deeper:

"Zeaxanthin" is not one molecule — it is a three-isomer family, and the foveal isomer is not what you eat. Dietary zeaxanthin is the 3R,3′R form (orange peppers, corn, egg yolk, saffron, goji). The form that dominates in the foveola — the highest-acuity central retinal region — is meso-zeaxanthin (3R,3′S), which is barely present in normal food and is instead generated inside the retina by enzymatic isomerization of dietary lutein. See §1 and §5.
AREDS2 is the most-cited study in this field and the most-mis-cited. AREDS2 tested an L 10 + Z 2 mg/d combination (layered onto the AREDS1 antioxidant base) — it was not a zeaxanthin standalone trial. Its primary endpoint was not statistically significant. Only in a secondary subgroup analysis of the lowest baseline L+Z dietary-intake quartile was a ~26% reduction in progression risk observed. Any reference to AREDS2 must specify "combination" and must not be split-attributed to zeaxanthin alone. See §4.
CREST and MOST AMD are two separate trials from the same Irish research group and they get confused constantly. MOST AMD (PMID 25976647) is a 36-month early-AMD trial in 67 patients; CREST is a separate 12-month two-arm RCT (methodology PMID 24621122 / Report 1 PMID 27367585, healthy population, contrast sensitivity endpoint). Citing CREST via PMID 25976647 is the most common literature error in this field; this page treats the distinction as a hard rule. See §5.2.

Bottom line: If your goal is general retinal-pigment maintenance, the AREDS2-ratio L 10 + Z 2 mg/d combination (taken with a fat-containing meal) is the de facto reference. If your goal is foveal meso-Z support, adequate dietary lutein intake itself maintains the foveal meso-Z pool because lutein is the in-retinal precursor. There is no need to chase a "must contain meso-Z" product unless a specific high-end protocol is being replicated. The honest evidence boundaries are spelled out in §4-§6, and the editorial / regulatory rules are spelled out in §11.

§2 · Three molecules, three stories — the stereochemistry that everything else depends on

Zeaxanthin is not one molecule but a three-isomer macular xanthophyll family (lutein 3R,3′R,6′R vs 3R,3′R-zeaxanthin vs meso-zeaxanthin 3R,3′S), all sharing formula C40H56O2 but differing in stereochemistry, which drives a radial macular pigment gradient (peripheral lutein → mid-peripheral zeaxanthin → foveal meso-Z) — and clinical data on one isomer cannot be extrapolated to another. (§1/§2)

Zeaxanthin is not "one molecule." It is a two-stereoisomer compound (3R,3′R + meso 3R,3′S), and it has a structural cousin (lutein) that shares the same molecular formula. All three together form the basis of the macular pigment system.

Molecule	Stereochemistry	Major food sources	Retinal deposition zone
Lutein	3R,3′R,6′R — one terminal ring is the asymmetric ε-ionone ring	Spinach, kale, corn, egg yolk	Macular periphery
3R,3′R-Zeaxanthin (dietary)	3R,3′R — both terminal rings are β-ionone	Orange bell pepper, saffron stigma, corn, wolfberry / goji, egg yolk	Macular mid-periphery
meso-Zeaxanthin	3R,3′S — meso (internally symmetric) configuration of the same β,β-skeleton	Barely present in normal foods; mostly generated inside the retina by enzymatic isomerization of dietary lutein	Foveola (centre of the central fovea) — highest-acuity zone

All three carry the molecular formula C40H56O2. They differ only in stereochemistry. That stereochemical difference drives different retinal deposition zones, which drives different evidence bases — and clinical data on one isomer cannot be extrapolated directly to another.

Three common mistakes that follow from missing this distinction:

"Zeaxanthin is just another word for lutein." False — different stereochemistry, different deposition zones, different trial bases.
"meso-Zeaxanthin can be obtained from food." Barely; the retinal isomerization pathway is the main physiological route, which is why adequate dietary lutein already supplies the foveal meso-Z pool indirectly.
"AREDS2 proved zeaxanthin protects vision." False — AREDS2 tested an L + Z combination, with a non-significant primary endpoint (see §4).

§3 · Honest food and absorption table

Most readers assume the answer is "corn." It is not.

Food	Zeaxanthin (mg per 100 g edible)	Notes
Saffron stigma (dried)	Tens to ~100 mg/100 g (order of magnitude)	Real-world daily intake is negligible — not a practical dietary source
Orange bell pepper	1.4-1.7 mg/100 g	The highest-content common vegetable
Corn (sweet corn / corn kernel)	0.5-0.9 mg/100 g	Mainstream source; kernel pigment is ~100% zeaxanthin
Egg yolk	0.2-0.3 mg per egg	Highest bioavailability — co-loaded with phosphatidylcholine and bile-cholesterol matrix
Goji / wolfberry (dried)	0.7-1.0 mg/100 g	Chemical basis of the traditional "eye-bright" use
Marigold (Tagetes erecta)	Industrial extraction feedstock	Not a food; primarily a commercial extraction substrate for supplements
Spinach / kale	< 0.3 mg/100 g	These dark leafy greens are dominated by lutein, not zeaxanthin

§3.1 · Why egg yolk is special — and why fat matters

Egg yolk does not have the highest absolute zeaxanthin content (0.2-0.3 mg per egg is modest), but it has the highest bioavailability of any common food source. The reason is matrix chemistry: yolk carotenoids are naturally pre-loaded into phospholipid vesicles (rich in phosphatidylcholine), which means they are already in a digestion-ready emulsion before they reach the duodenum. Plant-source carotenoids, by contrast, are locked inside chloroplast complexes or cellulose-bound matrices and require cooking + dietary fat to release.

This is the chemical basis for the dietary-guideline observation that "one egg per day is meaningful for eye health."

meso-Zeaxanthin almost never appears in common food. It is found in trace amounts in brine shrimp shells, certain fish roe, and marine crustacean exoskeletons — none of which contribute meaningfully to human intake. The dominant physiological route is the in-retinal isomerization of lutein via RPE65 / isomerase enzymes at the 3′ position. This is why supplementing lutein indirectly supports the foveal meso-Z pool, and why a "must contain meso-Z" supplement is not a requirement for most readers.

Absorption variables that actually move the needle

Dietary fat with the dose: taking zeaxanthin (or any fat-soluble carotenoid) with a fat-containing meal substantially raises plasma uptake. The foundational evidence is Kostic 1995 (PMID 7661123), a lutein + β-carotene fat-co-administration study whose mechanism extrapolates to zeaxanthin. Fasting administration substantially reduces uptake.
Fat-blocking medication: concurrent orlistat (or similar) reduces absorption — the standard fat-soluble-vitamin caution.
Individual variability: BCO1 / BCO2 enzyme polymorphisms, gut microbiome, age, and habitual intake all modulate absorption efficiency.
Stereochemistry: the natural 3R,3′R-zeaxanthin dominates food and most authorised supplements. Synthetic processes can produce non-natural stereoconfigurations whose absorption / deposition behaviour must be assessed case by case.

§3.2 · The radial macular pigment gradient — the unique zeaxanthin story

The macula is an elliptical region roughly 5.5 mm across at the back of the retina. Inside it sits the fovea (~1.5 mm), and at the very centre of the fovea is the foveola (~0.35 mm) — the avascular, rod-free, cone-dense zone that delivers the eye's highest spatial resolution.

Across this region, the three macular xanthophylls do not distribute uniformly. They form a radial gradient:

Retinal zone	Dominant pigment	Functional implication
Macular periphery	Lutein	Wide-field diffuse blue-light filtration
Macular mid-periphery	3R,3′R-Zeaxanthin	Mid-field blue-light filtration + antioxidant function
Foveola (~0.25-0.5° visual field)	meso-Zeaxanthin (3R,3′S)	Built-in optical filter at the eye's highest-acuity zone

This gradient has been documented repeatedly by Bone, Landrum, Sabour-Pickett, Nolan and colleagues over 20 years using post-mortem anatomic dissection, heterochromatic flicker photometry (HFP), and autofluorescence imaging. See Bone 2007 (PMID 17498306) and the Sabour-Pickett 2012 review (PMID 22121091).

§3.3 · MPOD — how the field measures the pigment

Macular pigment optical density (MPOD) is the standard quantitative measure of how thick this built-in retinal filter actually is. Methods include:

HFP (heterochromatic flicker photometry) — the most common non-invasive subjective measure
Autofluorescence / resonance Raman — objective methods but with expensive instrumentation
MP-eye / Macular Densitometer — consumer-grade and clinical devices

MPOD is reported on a 0-1.0 dimensionless optical-density scale. The healthy adult average is ~0.3-0.5; values above 0.7 define the "high MPOD" group. MPOD is the primary intermediate endpoint in the great majority of L/Z intervention RCTs — it is objectively measurable, exhibits clear dose-response with supplementation, and correlates with several visual-function endpoints (contrast sensitivity, glare recovery).

§4 · The role of zeaxanthin in AREDS2 — the "combination" rule and the actual numbers

RCT (combination, primary endpoint NS · secondary subgroup only)

AREDS2 tested an L 10 + Z 2 mg/d combination — not a zeaxanthin standalone trial; the primary endpoint was NOT statistically significant, and only in a secondary subgroup analysis of the lowest baseline L+Z intake quartile was an approximately 26% reduction in progression risk observed.

4,203adults aged 50-85, 5-year intervention RCT
~ -26%progression-risk reduction, lowest baseline L+Z intake quartile (secondary subgroup only)
5-year + 10-yearintervention + follow-up confirming long-term safety of combination

Hard rule: AREDS2 is a study of an L 10 mg + Z 2 mg/d combination (layered on the AREDS1 antioxidant base). It is not a zeaxanthin-standalone study. Any citation must specify "combination."

§4.1 · What AREDS2 is

AREDS2 (Age-Related Eye Disease Study 2) was the National Eye Institute multi-centre, double-blind, randomised controlled trial of 4,203 adults aged 50-85 with intermediate or contralateral late retinopathy, intervened over 5 years (PMID 23644932).

AREDS2 was designed to settle two questions left open by AREDS1 (2001):

Can the lutein + zeaxanthin combination replace β-carotene? (β-Carotene supplementation had been shown to increase lung cancer risk in smokers in the earlier CARET and ATBC trials.)
Does adding ω-3 fatty acids (DHA + EPA) provide additional benefit?

§4.2 · The 2 × 2 factorial design

Participants were randomised to one of four intervention arms, all layered onto the AREDS1 base of vitamin C / E + zinc + copper:

Arm	Added components
Placebo	—
L 10 + Z 2 mg/d ("combination" arm)	Lutein + zeaxanthin
DHA 350 + EPA 650 mg/d	ω-3 fatty acids
L + Z + DHA + EPA	Full combination

§4.3 · The honest reading of the AREDS2 results

#	Finding	Attributable to zeaxanthin alone?
1	The L 10 + Z 2 mg/d combination safely replaced β-carotene (no increased lung cancer signal in smokers)	Not splittable
2	Primary endpoint NOT statistically significant. Only in the lowest baseline L+Z dietary intake quartile (secondary subgroup analysis) was a ~26% reduction in progression risk observed	Not splittable, and only a secondary-subgroup result
3	Adding ω-3 (DHA + EPA) provided no additional endpoint benefit	—
4	10-year follow-up (Chew 2022, PMID 35653117) confirmed long-term safety of the L + Z + EPA + DHA combination and persistence of the β-carotene-substitution safety benefit	Still a combination conclusion

This is the reason this educational page and the downstream commercial pages must stay disciplined about language. The legitimate framing is: "AREDS2 found, with the L 10 + Z 2 mg + EPA + DHA combination, that …". The forbidden framing is: "zeaxanthin reduces AMD progression by 25%." That framing is both wrong about the study unit (combination, not standalone) and wrong about the number (primary NS · only the lowest-quartile secondary subgroup showed ~-26%).

An ancillary baseline / functional report from the same group (Akuffo 2017, PMID 27091854, BJO) provides the most-cited reference for the AREDS2 visual-function ancillary measures discussion.

§4.4 · The independent zeaxanthin RCT base — beyond AREDS2

RCT (standalone zeaxanthin · landmark independent trial)

Richer ZVF 2011 is the landmark independent zeaxanthin RCT: a standalone Z 8 mg arm in early-retinopathy patients showed significantly improved MPOD and contrast sensitivity and shortened glare recovery time.

60early-retinopathy patients, Z 8 mg vs L 9 mg vs placebo × 12 months
8 mgstandalone zeaxanthin daily dose studied (Richer ZVF)
1,176subjects in Ma 2016 meta-analysis, clear L/Z dose-response with MPOD + contrast sensitivity

Zeaxanthin does not "only exist in AREDS2." There is a small but real independent RCT base:

Study	Design	Key finding	PMID
Bone 2007	n = 10, zeaxanthin 20 mg or triple-formulation over 12 weeks	First quantitative confirmation that zeaxanthin alone elevates MPOD, with mid-peripheral deposition preference	17498306
Richer ZVF 2011 (Zeaxanthin and Visual Function Study)	n = 60 patients with early retinopathy, Z 8 mg vs L 9 mg vs placebo × 12 months	Z 8 mg arm showed significantly improved MPOD + contrast sensitivity, shortened glare recovery time; the landmark independent zeaxanthin RCT	22027699
Ma 2016 meta-analysis	1,176-subject systematic review	Clear dose-response relationship between L/Z supplementation, MPOD elevation, and contrast sensitivity improvement	27420092

§5 · meso-Zeaxanthin — the foveal story stays in its own section

The meso-zeaxanthin story is scientifically fascinating and commercially dangerous. It is broken out into its own section to make the educational language unambiguous about what it is, where it comes from, what the evidence supports, and what the evidence does NOT support.

§5.1 · What meso-zeaxanthin is — the in-retinal isomerization product

meso-Zeaxanthin is the meso (internally symmetric) 3R,3′S stereoisomer of zeaxanthin. Chemically, "meso" denotes a molecule with internal chirality centres that are optically inactive due to internal symmetry. Two formation routes exist:

Direct dietary intake (minor): trace amounts in brine shrimp shells, certain fish roe, and marine crustacean exoskeletons — not a meaningful human source.
In-retinal enzymatic isomerization (dominant): dietary lutein entering the retina is isomerized at the 3′ position by RPE65 / isomerase enzymes to meso-zeaxanthin, which then deposits in the foveola.

§5.2 · The key meso-Z intervention trials — CREST and MOST AMD must be strictly distinguished

RCT (triple-formulation only · not single-component attributable)

CREST and MOST AMD are two separate trials from the same Akuffo/Beatty/Nolan group; all key meso-Z trials used triple (L + Z + meso-Z) formulations, so the effect cannot be split-attributed to meso-Z alone, and PMID 25976647 (MOST AMD) must not be cited as CREST.

67early-AMD patients in MOST AMD, three L/Z/meso-Z formulations × 36 months (PMID 25976647)
105healthy adults in CREST Report 1, L 10 + Z 2 + MZ 10 mg/d × 12 months, improved contrast sensitivity + MPOD (PMID 27367585)
120 + 150CREST two-arm RCT (healthy + early-AMD) · 6-cpd contrast sensitivity

Important distinction: CREST and MOST AMD are two separate trials from the same Akuffo / Beatty / Nolan group. MOST AMD came first (n = 67 early-AMD patients · 36 months); CREST came after (a two-arm RCT, healthy n = 120 + early-AMD n = 150). They are not interchangeable. A PMID belonging to one trial must NOT be cited as the other.

Study	Design	Key finding	PMID
Bone 2007 (first triple-formulation trial)	n = 10, triple L/Z/meso-Z formulation × 12 weeks	First confirmation that dietary meso-Z is absorbed and deposits in the foveola	17498306
Nolan 2012 (atypical MPOD distribution)	n = 31 with central-foveal MPOD trough phenotype	Triple L/Z/MZ formulation reconstructed the central foveal MPOD peak in individuals with a "low-central" pigment distribution	22652506
MOST AMD Study · Akuffo 2015	n = 67 early retinopathy patients, three L/Z/meso-Z formulations sustained × 36 months (double-blind RCT · Eye (Lond) 29(7):902-12)	The meso-Z-containing triple formulation produced significantly greater central foveal MPOD increment than L + Z alone	25976647
CREST methodology · Akuffo 2014	Two-arm RCT design (healthy n = 120 + early retinopathy n = 150 · Central Retinal Enrichment Supplementation Trial methodology)	Defines the CREST two-trial design; primary endpoint = 6-cpd contrast sensitivity	24621122
CREST Report 1 · Nolan 2016	n = 105 healthy adults without retinal disease, L 10 + Z 2 + MZ 10 mg/d × 12 months vs placebo	Triple supplementation significantly improved contrast sensitivity + MPOD in a healthy population — i.e., functional improvement measurable in non-AMD subjects	27367585
Sabour-Pickett 2012 (comprehensive review)	—	Systematic synthesis of L/Z/MZ as the three components of macular pigment and of MPOD as a legitimate surrogate endpoint	22121091
Nolan AD 2015	n = 31 Alzheimer's patients, L + Z + MZ × 6 months	MPOD rose significantly, cognitive scores showed early exploratory improvement trend	25408222

§5.3 · The honest meso-Z evidence boundary

Hard rule (consistent with the NC regulatory-status.md):

Defensible: "meso-Zeaxanthin is the dominant pigment component in the central foveola" — a composition / mechanism fact.
Defensible: "meso-Zeaxanthin can be generated in the retina from dietary lutein via enzymatic isomerization" — a physiology fact.
Defensible: "MOST AMD and CREST triple-formulation trials observed central foveal MPOD elevation" — a combination conclusion stated as such.
Not defensible: "meso-Z protects central vision" — function claim + disease implication.
Not defensible: "MOST AMD or CREST proved standalone meso-Z elevates central foveal MPOD" — single-component attribution from a triple-formulation trial.
Not defensible: "Foveal vision requires meso-Z supplementation" — lutein is the in-retinal precursor that supports the same pool indirectly.

The educational stance is to present meso-Z as a scientifically important macular constituent — and to let the reader understand why adequate lutein intake is itself meaningful to the foveal compartment, rather than packaging meso-Z as "the next miracle ingredient."

§6 · Blue light and contrast sensitivity — evidence tier discipline

Zeaxanthin's absorption peaks at ~470 nm in the high-energy blue band, so a high macular pigment optical density (MPOD) acts as a built-in retinal blue-light filter with a parallel singlet-oxygen-quenching antioxidant function; meso-Z is generated inside the retina by enzymatic isomerization of dietary lutein via RPE65/isomerase. (§3.2/§5.1/§6.1)

§6.1 · The blue-light filtration mechanism (tier A · consensus)

Zeaxanthin's molecular absorption spectrum peaks at ~470 nm — exactly within the high-energy band of visible blue light (400-500 nm). Photochemically, prolonged high-energy blue light exposure damages photoreceptors and the retinal pigment epithelium through singlet-oxygen pathways. A high MPOD acts as a built-in retinal blue-light filter that physically intercepts a fraction of the incident high-energy photons before they reach the photoreceptor outer segments.

This is a textbook-level mechanism consensus, not a controversial claim — but at the educational level, the claim must remain mechanistic ("acts as a built-in optical filter") rather than disease-protective.

§6.2 · Digital eye strain / heavy screen users (tier B · healthy-population RCT)

Study	Design	Finding	PMID
Stringham 2017	n = 59 heavy screen users, L 10 + Z 2 mg/d combination × 6 months	Significant improvement in visual fatigue scores, headache frequency, eye discomfort, sleep quality; MPOD rose in parallel	28661438
Ma 2009	n = 37 computer-using office workers, L 6 or 12 mg/d × 12 weeks	12 mg arm showed significant improvement in glare sensitivity and contrast sensitivity; visual discomfort reduced (note: lutein-only intervention, included as same-family extrapolation reference)	19586568

Note that Stringham 2017 is an L + Z combination intervention — the "combination rule" applies. The legitimate framing is "the AREDS2-ratio L + Z combination," not "zeaxanthin alone."

§6.3 · Contrast sensitivity and glare recovery (tier B · healthy + early-retinopathy RCTs with strict population separation)

Study	Population	Design	Finding	PMID
Richer ZVF 2011	Early-retinopathy patients	n = 60, Z 8 mg standalone vs L 9 mg vs placebo × 12 months	The Z 8 mg standalone arm significantly improved contrast sensitivity and shortened glare recovery time — the most important zeaxanthin-standalone functional evidence in the literature	22027699
CREST Report 1 · Nolan 2016	Healthy (no retinal disease)	n = 105, L 10 + Z 2 + MZ 10 mg/d × 12 months vs placebo	Triple supplementation significantly improved contrast sensitivity + MPOD in a healthy population	27367585
MOST AMD · Akuffo 2015	Early-retinopathy patients	n = 67, three L/Z/meso-Z formulations × 36 months	meso-Z-containing triple arm produced significantly greater central foveal MPOD increment than L + Z alone	25976647
Yao 2013	Chinese professional drivers	n = 120, L 12-24 mg × 12 months	The high-L arm significantly improved night-time contrast sensitivity and glare recovery (note: lutein-only intervention, included as family-level reference)	23360692
Ma 2016 meta-analysis	Systematic review	1,176 subjects	Clear dose-response for L/Z supplementation → MPOD rise → contrast sensitivity improvement	27420092

Strict-distinction reminder: when downstream content references any of the above trials, the population label ("healthy" vs "early retinopathy patients") must be carried alongside the citation. Cross-population extrapolation distorts the effect-size meaning.

§6.4 · Cognition and skin (tier C+/C — included for completeness, not as headline claims)

These directions are not the primary zeaxanthin narrative, but they are included at the educational level for honesty:

Direction	Key study	Strength	PMID
Cognition (middle-aged and older)	Power 2018 MacuPrime (n = 91, L 10 + Z 2 + MZ 10 × 12 months, triple formulation)	C+ — improved spatial memory and processing speed in baseline-low-MPOD individuals	29332050
Cognition · centenarian brain tissue	Johnson 2013 (n = 76 oldest-old cohort · cross-sectional)	Mechanistic plausibility — brain tissue L/Z concentrations correlate positively with cognitive scores	23840953
Skin antioxidant / photoprotection	Juturu 2016 (n = 50 healthy women · L 10 + Z 2 × 12 weeks combination)	C — improvement in skin-tone uniformity, hydration, elasticity	27785083
Skin · oral + topical	Palombo 2007 (n = 40 · L/Z oral + topical × 12 weeks combination)	C — reduced skin lipid peroxidation, improved barrier hydration and elasticity	17446716

§7 · Safety, upper intake, and population notes

Indicator	Value / conclusion	Source
NOAEL (rat · 52 weeks)	Zeaxanthin ≥ 400 mg/kg bw/d; meso-zeaxanthin ≥ 300 mg/kg bw/d	Industry GRAS dossiers
EFSA ADI	≤ 0.75 mg/kg body weight / day (~53 mg/d for a 70-kg adult)	EFSA 2012 ANS Panel Opinion
AREDS2 long-term tolerance	L 10 + Z 2 mg/d combination × 5 years + 10-year follow-up with no serious adverse events	PMID 23644932 + PMID 35653117
Common adverse effects	Very rare; very high long-term doses can produce mild reversible skin yellowing (carotenodermia, class effect with β-carotene); resolves on discontinuation	RCT consensus
Smokers	Unlike β-carotene, AREDS2 confirmed L + Z combination substitution is SAFER for smokers (no lung cancer signal)	PMID 23644932
Pregnancy / breastfeeding	No dedicated high-dose supplementation safety data; consult a clinician	—
Children	Ordinary dietary intake (eggs, corn, greens) is safe; high-dose supplementation not systematically studied	—
Drug interactions	Concurrent orlistat or other fat-blocking medication reduces absorption (fat-soluble caution); take with fat-containing meal; no anticoagulant interaction reported	PMID 7661123

Concept clarification: the EFSA ADI (Acceptable Daily Intake, expressed per kg body weight) and a UL (Tolerable Upper Intake Level, expressed per total daily amount) are not exactly the same construct. Most jurisdictions have NOT set a separate official UL for zeaxanthin, so the EFSA ADI is currently the most authoritative reference number.

§8 · Three-region regulatory snapshot

Full regulatory detail lives in the NC T1-Zeaxanthin/regulatory-status.md. This section is a fact-sheet-level snapshot.

Dimension	United States · FDA	China · NMPA	Brazil · ANVISA
Regulatory identity	Dietary supplement + GRAS (marigold / fermentation / synthetic meso routes have self-affirmed GRAS notifications)	Lutein ester is the registered functional health-food raw material (zeaxanthin can be a co-component); standalone zeaxanthin not independently listed	RDC 243/2018 dietary supplement framework
Permissible claims	Structure/Function Claims (with FDA 30-day notification)	"Relieves visual fatigue" function requires functional-health-food registration	General eye-health context only
Mandatory disclaimer	"This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease."	Must carry the functional-health-food / general-food regulatory identity statement	Must carry the ANVISA dietary-supplement compliance label
Commercial doses	Z 2-10 mg/d; AREDS2 ratio L 10 + Z 2 mg	Per functional-health-food regulations	Per ANVISA IDR
meso-Z standalone	GRAS (multiple self-affirmed notifications)	Approved as a Novel Food in 2024 (marigold-derived process route)	Case-by-case confirmation
Disease claims	Prohibited (AMD / macular degeneration / glaucoma / cataract / myopia and similar disease names are all prohibited)	Prohibited	Prohibited

2024 China update: meso-zeaxanthin was approved as a Novel Food (marigold-oleoresin process route). This is the key milestone for the legal market entry of standalone meso-Z products in the China dietary-supplement context.

§9 · Two purchasing dimensions — L:Z ratio origin and whether meso-Z needs to be supplemented separately

AREDS2-ratio L 10 + Z 2 mg/d combination (with a fat-containing meal) is the de facto reference; standalone Z 8 mg/d was studied in Richer ZVF 2011, meso-Z 10 mg/d in CREST/MOST AMD triple protocols, and the EFSA ADI is 0.75 mg/kg bw/d (~53 mg/d for a 70-kg adult). (§9.1/§7/Tags)

This educational page does not endorse specific products. But two reader questions are common enough that they deserve a fact-level answer.

§9.1 · Where does L:Z = 10:2 come from?

The 5:1 ratio comes directly from the AREDS2 intervention arm design (L 10 mg + Z 2 mg/d). It is not a "natural optimal ratio" and it is not a "maximum efficacy ratio." It was a research dose chosen by AREDS2 investigators based on safety, supply availability, and the dietary epidemiology of the time.

The reason the industry treats it as a de facto gold standard is that AREDS2 remains the largest and longest (5-year intervention + 10-year follow-up) RCT in the field, so market language and regulatory framing both anchor to it (PMID 23644932 / PMID 35653117).
Some research used the L 10 + Z 2 + MZ 10 mg/d triple formulation (MOST AMD / CREST / LUNA / MacuPrime) to study the incremental meso-Z contribution.
Standalone high-dose zeaxanthin (e.g., Z 8 mg in Richer ZVF 2011) exists in the scientific literature but commercial products at that dose are rare.

§9.2 · Does meso-Z need to be supplemented separately?

Fact-sheet answer: it depends on the reader's framing — but adequate dietary lutein intake itself maintains the foveal meso-Z pool.

Angle	Fact statement
Physiology	The human retina generates meso-zeaxanthin from dietary lutein via enzymatic isomerization; adequate lutein intake itself supports the foveal meso-Z pool indirectly
RCT evidence	Standalone meso-Z hard-endpoint data are limited; the key trials (MOST AMD / CREST / LUNA / MacuPrime) all used triple formulations and the effect cannot be split-attributed to meso-Z alone
Regulatory	China only approved meso-Z as a Novel Food in 2024; U.S. has GRAS but the ingredient remains relatively niche
Purchasing context	High-end clinical channels favour the triple formulation as a positioning device; the mainstream market continues to anchor on the AREDS2 L 10 + Z 2 mg combination

Note that this page does not judge whether any specific product "must" contain meso-Z. Specific product selection should be made with a qualified clinician and should reference the registered compliant claims available in the relevant market.

§10 · Cluster sibling sub-pages — the five-node carotenoid network

This sub-page sits inside the carotenoids cluster hub. The five sibling links below are the structural backbone of the family-level narrative:

Lutein (3R,3′R,6′R-xanthophyll) — Macular pair partner of zeaxanthin · the dominant carotenoid in peripheral macula · the in-retinal precursor of meso-zeaxanthin · the L of the AREDS2 L 10 + Z 2 mg/d combination · the strongest single cross-link in this sub-page
Carotenoids (cluster hub) — Parent cluster hub covering the eight major carotenoid compounds (carotene and xanthophyll subfamilies); zeaxanthin is the macular-targeted xanthophyll within this family
Lycopene (acyclic carotene) — Sibling carotenoid but in the carotene subfamily (no oxygen) — prostate and cardiovascular targets rather than retina — useful as a reader anchor that "carotenoid is not one thing"
β-Carotene (provitamin A carotene) — Historical lesson anchor — CARET / ATBC trials showed high-dose β-carotene supplementation increases lung cancer risk in smokers, which is the direct reason AREDS2 substituted L + Z for β-carotene
Astaxanthin (keto-xanthophyll) — Same xanthophyll subfamily but a bipolar keto + hydroxy terminal structure — broad-spectrum antioxidant with blood-brain-barrier penetration, mechanism and tropism differ from zeaxanthin

§12 · References

All zeaxanthin-specific PMIDs verified against PubMed (2026-05-24). Effect sizes are reported as published. Brand names appearing in supplier / regulatory contexts (FloraGLO®, OptiSharp®, ZeaGLO®, Lutemax 2020®, CaroCare®, MacuHealth MZ® and similar trademarks) are referenced as generic categories only and are not endorsed by this page.

Zeaxanthin-specific PMIDs cited on this page (19 verified)

PMID 23644932 · AREDS2 Research Group (2013) · "Lutein + zeaxanthin and omega-3 fatty acids for AMD: AREDS2 randomized clinical trial" · JAMA · n = 4,203 · L 10 + Z 2 mg/d combination layered on AREDS1 antioxidant base · 5-year intervention · primary endpoint NS · lowest baseline L+Z intake quartile secondary ~ -26% progression risk
PMID 35653117 · Chew EY et al. (2022) · AREDS2 10-year follow-on · JAMA Ophthalmology · n = 3,882 · long-term safety of L + Z + EPA + DHA combination and persistence of β-carotene-substitution safety benefit
PMID 22027699 · Richer SP et al. (2011) · Zeaxanthin and Visual Function Study (ZVF) · Optometry · n = 60 · standalone Z 8 mg vs L 9 mg vs placebo × 12 months · improved MPOD + contrast sensitivity + glare recovery in the Z arm — the landmark independent zeaxanthin RCT
PMID 25976647 · Akuffo KO et al. (2015) · MOST AMD Study · Eye (Lond) 29(7):902-12 · n = 67 early-AMD patients · three L/Z/meso-Z formulations × 36 months · the meso-Z-containing triple arm produced greater central foveal MPOD increment than L + Z alone — NOT CREST
PMID 24621122 · Akuffo KO et al. (2014) · CREST methodology · Ophthalmic Epidemiology · defines the CREST two-arm RCT design (healthy n = 120 + early-AMD n = 150) with 6-cpd contrast sensitivity as the primary endpoint
PMID 27367585 · Nolan JM et al. (2016) · CREST Report 1 · Invest Ophthalmol Vis Sci · n = 105 healthy adults · L 10 + Z 2 + MZ 10 mg/d × 12 months · significant improvement in contrast sensitivity + MPOD in a healthy population
PMID 27091854 · Akuffo KO et al. (2017) · British Journal of Ophthalmology · AREDS2-context baseline visual-function ancillary report
PMID 17498306 · Bone RA, Landrum JT (2007) · macular pigment distribution and meso-zeaxanthin foveal localization · foundational reference for the radial macular pigment gradient
PMID 22121091 · Sabour-Pickett S, Nolan JM et al. (2012) · comprehensive review of macular carotenoids · synthesis of L/Z/meso-Z as the three components of macular pigment and of MPOD as a legitimate surrogate endpoint
PMID 22652506 · Nolan JM et al. (2012) · atypical MPOD distribution · n = 31 with central-foveal MPOD trough · triple L/Z/MZ formulation reconstructed the central peak
PMID 28661438 · Stringham JM et al. (2017) · n = 59 high-screen users · L + Z combination × 6 months · improved visual fatigue, headaches, eye discomfort, sleep quality + parallel MPOD elevation
PMID 19586568 · Ma L et al. (2009) · n = 37 computer-using office workers · L 6 or 12 mg/d × 12 weeks · 12 mg arm improved glare and contrast sensitivity (lutein-only intervention, same-family extrapolation reference)
PMID 23360692 · Yao Y et al. (2013) · n = 120 Chinese professional drivers · L 12-24 mg × 12 months · high-L arm improved night-time contrast sensitivity and glare recovery (lutein-only intervention, family-level reference)
PMID 27420092 · Ma L et al. (2016) · systematic review + dose-response meta-analysis · 1,176 subjects · L/Z dose-response with MPOD elevation and contrast sensitivity improvement
PMID 29332050 · Power R et al. (2018) · MacuPrime · n = 91 · L 10 + Z 2 + MZ 10 × 12 months triple formulation · improved spatial memory + processing speed in baseline-low-MPOD individuals (C+ evidence tier)
PMID 23840953 · Johnson EJ et al. (2013) · n = 76 oldest-old centenarian cohort · cross-sectional · brain tissue L/Z concentrations correlate with cognitive scores (mechanistic plausibility)
PMID 25408222 · Nolan JM et al. (2015) · n = 31 Alzheimer's patients · L + Z + MZ × 6 months · MPOD rose significantly, cognitive scores trended toward improvement (exploratory)
PMID 27785083 · Juturu V et al. (2016) · n = 50 healthy women · L 10 + Z 2 × 12 weeks combination · skin-tone uniformity, hydration, elasticity improved (C-tier)
PMID 17446716 · Palombo P et al. (2007) · n = 40 · L/Z oral + topical × 12 weeks combination · reduced skin lipid peroxidation; improved barrier hydration and elasticity (C-tier)

Supporting reference

PMID 7661123 · Kostic D, White WS, Olson JA (1995) · the foundational lutein + β-carotene fat-co-administration absorption study; mechanism extrapolates to zeaxanthin and is the source for the "take with a fat-containing meal" rule

Regulatory and Public-Health References (not counted in the PMID total)

EFSA · 2012 ANS Panel Opinion · Acceptable Daily Intake (ADI) for zeaxanthin set at 0.75 mg/kg body weight / day
EFSA · Commission Regulation (EU) 2017/2470 · synthetic / fermented zeaxanthin Novel Food authorisation list with maximum-use-level limits
FDA · Dietary Supplement + GRAS framework; Structure / Function Claims permitted with 30-day notification; disease claims prohibited
NMPA China · Lutein ester listed as the registered functional health-food raw material with the relieve-visual-fatigue function; meso-zeaxanthin approved as a Novel Food in 2024 (marigold-derived process route)
ANVISA Brazil · RDC 243/2018 dietary supplement framework; general eye-health context permitted
AREDS / AREDS2 trial backgrounds · earlier CARET and ATBC trials established the lung cancer risk signal of β-carotene supplementation in smokers, which is the direct reason AREDS2 substituted L + Z for β-carotene

Cross-links

Parent hub: Carotenoids cluster page →
Macular-pair sibling sub-page (strongest cross-link): Lutein →
Family-level sibling sub-pages: Lycopene → · β-Carotene → · Astaxanthin →
Eye-protection goal page: Eye protection goal →

Educational Disclaimer

This page is educational content and is not medical advice. It does not diagnose, treat, cure, or prevent any disease. Zeaxanthin is not a substitute for ophthalmology evaluation or any prescribed medication. Consult a qualified healthcare provider for individual recommendations, especially if you are pregnant, breastfeeding, on prescription medication, or managing a chronic eye or systemic condition. Brand and product names referenced in upstream regulatory or supply-chain context are not endorsed; the criteria described (AREDS2-ratio combination dosing, fat-containing meal co-administration, third-party-tested manufacturing, stereochemistry transparency, and clear distinction between standalone zeaxanthin and triple-formulation evidence) are evidence-based generic standards that any compliant product can meet. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

§11 · Frequently Asked Questions

The questions below are the most-searched questions on zeaxanthin across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.

1. Are zeaxanthin and lutein the same thing?

No. They share the same molecular formula (C40H56O2) but differ in stereochemistry. Lutein is 3R,3′R,6′R (one terminal ring is an asymmetric ε-ionone ring). Zeaxanthin is 3R,3′R (both terminal rings are β-ionone). They deposit in different regions of the retina (lutein in the peripheral macula, zeaxanthin in the mid-peripheral macula), and clinical data on one cannot be extrapolated directly to the other. See §1.

2. What is the best food source of zeaxanthin?

Orange bell pepper (1.4-1.7 mg per 100 g) and saffron stigma (highest by mass, but impractical daily intake) lead the list. The realistic everyday sources are corn, orange peppers, and egg yolk. Egg yolk has a relatively modest absolute amount (0.2-0.3 mg per egg) but the highest bioavailability because the carotenoids are co-loaded with lecithin phospholipids. See §2.

3. What is meso-zeaxanthin? Do I need to supplement it separately?

meso-Zeaxanthin is the meso-stereoisomer of zeaxanthin (3R,3′S), the dominant macular pigment in the foveola — the highest-acuity retinal region. The honest answer on supplementation is that adequate dietary lutein intake itself maintains the foveal meso-Z pool, because lutein is the in-retinal precursor that gets isomerized to meso-Z. Standalone hard-endpoint RCTs of meso-Z are limited; the key trials (MOST AMD, CREST, LUNA, MacuPrime) all used triple-supplement (L + Z + meso-Z) formulations and the data cannot be attributed to meso-Z alone. See §5 and §9.2.

4. Did AREDS2 prove that zeaxanthin prevents age-related macular degeneration?

No. AREDS2 tested an L 10 + Z 2 mg/d combination (layered onto the AREDS1 antioxidant base of vitamin C, vitamin E, zinc, and copper) — it was not a zeaxanthin standalone trial. The primary endpoint was NOT statistically significant. Only in a secondary subgroup analysis of the lowest baseline L+Z intake quartile was an approximately 26% reduction in progression risk observed. Any reference to AREDS2 must specify "combination" and must not be split-attributed to zeaxanthin alone. See §4.

5. Where did the L:Z = 10:2 ratio come from?

Directly from the AREDS2 intervention arm design (10 mg lutein + 2 mg zeaxanthin per day). It is NOT a "natural optimal ratio" or a "maximum efficacy ratio" — it was a research dose chosen by AREDS2 investigators balancing safety, supply availability, and the dietary epidemiology of the time. The reason the industry treats it as a de facto gold standard is that AREDS2 remains the largest and longest (5-year intervention + 10-year follow-up) RCT in the field, so market language and regulatory framing anchor to it. See §9.1.

6. Does zeaxanthin actually protect against blue light?

At the mechanism level, yes — zeaxanthin’s absorption peak is at 470 nm, exactly in the high-energy blue band (400-500 nm), and a high macular pigment optical density (MPOD) acts as a built-in retinal blue-light filter. In a randomized trial of high-screen users (Stringham 2017, PMID 28661438), an L + Z combination over 6 months improved visual fatigue scores, headache frequency, eye discomfort, and sleep quality. As with AREDS2, the trial used the combination, not zeaxanthin alone. See §6.1-6.2.

7. Is there an upper limit for zeaxanthin? What happens if I take too much?

The EFSA Acceptable Daily Intake (ADI) is 0.75 mg/kg body weight/day, which works out to approximately 53 mg/day for a 70-kg adult. AREDS2 found no serious adverse events at the L 10 + Z 2 mg/d combination over 5 years and a 10-year follow-up. Very high long-term doses can produce mild reversible skin yellowing (carotenodermia, a class effect shared with β-carotene) that resolves on discontinuation. Most countries have not set a separate official UL for zeaxanthin. See §7.

8. Is zeaxanthin safe for everyone?

Ordinary dietary intake (eggs, corn, leafy greens) is safe across populations. Unlike β-carotene, AREDS2 confirmed that L + Z substitution for β-carotene is safer for smokers (no lung cancer signal). Pregnancy, breastfeeding, and pediatric populations lack dedicated high-dose supplementation safety data; consult a clinician. See §7.

9. Should I take zeaxanthin with food or on an empty stomach?

With a fat-containing meal. Zeaxanthin is a fat-soluble carotenoid and absorption rises sharply when taken with dietary fat (Kostic 1995, PMID 7661123 — the foundational lutein + β-carotene fat-absorption study whose mechanism extrapolates to zeaxanthin). Fasting administration substantially reduces uptake. Concurrent use of orlistat or other fat-blocking medications also reduces absorption (the standard fat-soluble-vitamin caution). See §3.1 and §7.

10. Are CREST and MOST AMD the same trial?

No — they are two separate trials from the same Irish research group (Akuffo / Beatty / Nolan). MOST AMD (PMID 25976647, Akuffo 2015, Eye (Lond)) was a 36-month trial in 67 early-AMD patients comparing three L/Z/meso-Z formulations. CREST (Central Retinal Enrichment Supplementation Trial) is a separate two-arm RCT: methodology paper PMID 24621122 (Akuffo 2014) and Report 1 PMID 27367585 (Nolan 2016, healthy population, 12-month L 10 + Z 2 + meso-Z 10 mg/d on contrast sensitivity). The PMIDs are not interchangeable and CREST must not be cited via PMID 25976647. See §5.2.

11. What is the difference between zeaxanthin and astaxanthin?

Both are xanthophylls (oxygenated carotenoids), but astaxanthin has additional keto + hydroxy groups (a distinctive bipolar terminal structure), can cross the blood-brain barrier, and acts as a broad-spectrum antioxidant in muscle / skin / brain / retina. Zeaxanthin specifically deposits in the macular pigment of the retina. Mechanism and tissue tropism differ substantially. See §10 and the carotenoids hub.

12. What is the regulatory status of zeaxanthin in China and the EU?

China NMPA: the registered functional health-food raw material is lutein ester (with the relieve-visual-fatigue function), where zeaxanthin can appear as a co-component; standalone zeaxanthin has not been independently listed. In 2024 China approved meso-zeaxanthin as a Novel Food (marigold-derived process route). EU EFSA: synthetic / fermented zeaxanthin is on the Commission Regulation (EU) 2017/2470 Novel Food authorisation list with maximum-use-level limits, but L/Z specific macular-health function claims have NOT been authorised (EFSA rejected several Article 13 applications); only general antioxidant context is permitted. U.S. FDA: dietary supplement + GRAS; Structure / Function Claims permitted with the 30-day notification; disease claims prohibited. See §8.

← Back to Carotenoids cluster hub · All Ingredients